Long-term comparison between idarubicin and daunorubicin in the treatment of acute myeloid leukemia in young subjects

被引：0
|
作者：
Cluzeau, Thomas
机构：
来源：
HEMATOLOGIE | 2014年 / 20卷 / 02期
关键词：
D O I：
10.1684/hma.2014.0921
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：85 / 86
页数：2
相关论文
共 50 条
  • [1] Long term comparison between Idarubicin and Daunorubicin in the treatment of acute myeloid leukemia in a young subject (vol 20, pg 85, 2014)
    不详
    HEMATOLOGIE, 2014, 20 (03): : 141 - 141
  • [2] CYTARABIN AND DAUNORUBICIN OR IDARUBICIN IN INDUCTION THERAPY OF ACUTE MYELOID LEUKEMIA PATIENTS
    Eivazi-Ziaei, Jamal
    Kermani, Iraj Asvadi
    Nikanfar, Alireza
    Maljaie, Hadi
    Mahmoudpour, Ali
    Dolatkhah, Roya
    Golchin, Mehri
    Vaez, Jalil
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2009, 25 (05) : 829 - 832
  • [3] Superior Long-Term Outcome With Idarubicin Compared With High-Dose Daunorubicin in Patients With Acute Myeloid Leukemia Age 50 Years and Older
    Gardin, Claude
    Chevret, Sylvie
    Pautas, Cecile
    Turlure, Pascal
    Raffoux, Emmanuel
    Thomas, Xavier
    Quesnel, Bruno
    de Revel, Thierry
    de Botton, Stephane
    Gachard, Nathalie
    Renneville, Aline
    Boissel, Nicolas
    Preudhomme, Claude
    Terre, Christine
    Fenaux, Pierre
    Bordessoule, Dominique
    Celli-Lebras, Karine
    Castaigne, Sylvie
    Dombret, Herve
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (03) : 321 - 327
  • [4] Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia
    Berman, E
    Wiernik, P
    Vogler, R
    VelezGarcia, E
    Bartolucci, A
    Whaley, FS
    CANCER, 1997, 80 (11) : 2181 - 2185
  • [5] Daunorubicin for the treatment of acute myeloid leukemia
    Bertuzzi, Clara
    Paolini, Stefania
    Visani, Giuseppe
    Piccaluga, Pier Paolo
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (10): : 1075 - 1087
  • [6] Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia
    C Récher
    M C Béné
    B Lioure
    A Pigneux
    N Vey
    J Delaunay
    I Luquet
    M Hunault
    D Guyotat
    D Bouscary
    N Fegueux
    E Jourdan
    S Lissandre
    M Escoffre-Barbe
    C Bonmati
    E Randriamalala
    R Guièze
    M Ojeda-Uribe
    F Dreyfus
    J L Harousseau
    J Y Cahn
    N Ifrah
    P Guardiola
    Leukemia, 2014, 28 : 440 - 443
  • [7] Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia
    Recher, C.
    Bene, M. C.
    Lioure, B.
    Pigneux, A.
    Vey, N.
    Delaunay, J.
    Luquet, I.
    Hunault, M.
    Guyotat, D.
    Bouscary, D.
    Fegueux, N.
    Jourdan, E.
    Lissandre, S.
    Escoffre-Barbe, M.
    Bonmati, C.
    Randriamalala, E.
    Guieze, R.
    Ojeda-Uribe, M.
    Dreyfus, F.
    Harousseau, J. L.
    Cahn, J. Y.
    Ifrah, N.
    Guardiola, P.
    LEUKEMIA, 2014, 28 (02) : 440 - 443
  • [8] A Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in the Induction Chemotherapy for Acute Myeloid Leukemia
    Lee, Je-Hwan
    Kim, Hawk
    Joo, Young-Don
    Lee, Won Sik
    Bae, Sung Hwa
    Zang, Dae Young
    Kwon, Jihyun
    Kim, Min Kyoung
    Lee, Junglim
    Lee, Gyeong Won
    Lee, Jung-Hee
    Choi, Yunsuk
    Kim, Dae-Young
    Lim, Sung-Nam
    Lee, Sang-Min
    Ryoo, Hun-Mo
    Kim, Hyo Jung
    Hyun, Myung Soo
    Lee, Kyoo-Hyung
    BLOOD, 2015, 126 (23)
  • [9] COMPARISON OF THE INTRACELLULAR PHARMACOKINETICS OF DAUNORUBICIN AND IDARUBICIN IN PATIENTS WITH ACUTE-LEUKEMIA
    TIDEFELT, U
    SUNDMANENGBERG, B
    PAUL, C
    LEUKEMIA RESEARCH, 1994, 18 (04) : 293 - 297
  • [10] Cytarabine and daunorubicin for the treatment of acute myeloid leukemia
    Murphy, Tracy
    Yee, Karen W. L.
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (16) : 1765 - 1780
12345